Editas Medicine, Inc. (EDIT)

Editas Medicine Statistics

Total Valuation

Editas Medicine has a market cap or net worth of $222.10 million. The enterprise value is $64.74 million.

Market Cap	222.10M
Enterprise Value	64.74M

Important Dates

The last earnings date was Friday, October 31, 2025, before market open.

Earnings Date	Oct 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Editas Medicine has 89.92 million shares outstanding. The number of shares has increased by 1.46% in one year.

Current Share Class	89.92M
Shares Outstanding	89.92M
Shares Change (YoY)	+1.46%
Shares Change (QoQ)	+1.63%
Owned by Insiders (%)	0.39%
Owned by Institutions (%)	46.67%
Float	89.57M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.28
Forward PS	16.33
PB Ratio	11.25
P/TBV Ratio	11.57
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1.66
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.77, with a Debt / Equity ratio of 1.10.

Current Ratio	2.77
Quick Ratio	2.72
Debt / Equity	1.10
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-37.96

Financial Efficiency

Return on equity (ROE) is -188.58% and return on invested capital (ROIC) is -64.62%.

Return on Equity (ROE)	-188.58%
Return on Assets (ROA)	-33.76%
Return on Invested Capital (ROIC)	-64.62%
Return on Capital Employed (ROCE)	-111.17%
Revenue Per Employee	$158,134
Profits Per Employee	-$962,841
Employee Count	246
Asset Turnover	0.13
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -24.70% in the last 52 weeks. The beta is 2.42, so Editas Medicine's price volatility has been higher than the market average.

Beta (5Y)	2.42
52-Week Price Change	-24.70%
50-Day Moving Average	3.23
200-Day Moving Average	2.24
Relative Strength Index (RSI)	31.19
Average Volume (20 Days)	2,742,432

Short Selling Information

The latest short interest is 7.62 million, so 8.47% of the outstanding shares have been sold short.

Short Interest	7.62M
Short Previous Month	7.46M
Short % of Shares Out	8.47%
Short % of Float	8.51%
Short Ratio (days to cover)	2.34

Income Statement

In the last 12 months, Editas Medicine had revenue of $38.90 million and -$236.86 million in losses. Loss per share was -$2.85.

Revenue	38.90M
Gross Profit	-100.12M
Operating Income	-160.80M
Pretax Income	-236.86M
Net Income	-236.86M
EBITDA	-154.07M
EBIT	-160.80M
Loss Per Share	-$2.85

Balance Sheet

The company has $178.50 million in cash and $21.14 million in debt, giving a net cash position of $157.37 million or $1.75 per share.

Cash & Cash Equivalents	178.50M
Total Debt	21.14M
Net Cash	157.37M
Net Cash Per Share	$1.75
Equity (Book Value)	19.19M
Book Value Per Share	0.22
Working Capital	116.86M

Cash Flow

In the last 12 months, operating cash flow was -$201.36 million and capital expenditures -$3.58 million, giving a free cash flow of -$204.94 million.

Operating Cash Flow	-201.36M
Capital Expenditures	-3.58M
Free Cash Flow	-204.94M
FCF Per Share	-$2.28

Margins

Gross Margin	-257.38%
Operating Margin	-413.35%
Pretax Margin	-608.88%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Editas Medicine does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.46%
Shareholder Yield	n/a
Earnings Yield	-106.64%
FCF Yield	-92.27%

Analyst Forecast

The average price target for Editas Medicine is $4.56, which is 84.62% higher than the current price. The consensus rating is "Buy".

Price Target	$4.56
Price Target Difference	84.62%
Analyst Consensus	Buy
Analyst Count	11
Revenue Growth Forecast (5Y)	-15.61%
EPS Growth Forecast (5Y)	-18.10%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Editas Medicine has an Altman Z-Score of -11.64 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-11.64
Piotroski F-Score	1